Pfizer Pharmaceuticals Korea carry out patent support program of ‘Ibrance,’ breast cancer treatment

Pfizer Pharmaceuticals Korea will start a patient support program for ‘Ibrance(generic name: palbociclib),’ a breast cancer therapy.

According to the company, it internally had discussions about the program for the past several months and decided to carry out it within the coming June. The program is expected to temporarily run during the Ibrance’s health insurance benefit procedure, and the c...